Back to Journals » ClinicoEconomics and Outcomes Research » Volume 4

Treatment profiles and costs of patients with chronic pain in the population setting

Authors Mainar AS, Navarro Artieda R, Villoria Morillo J, Esquivias Escobar A

Received 12 September 2011

Accepted for publication 26 October 2011

Published 26 January 2012 Volume 2012:4 Pages 39—47

DOI https://doi.org/10.2147/CEOR.S26116

Review by Single-blind

Peer reviewer comments 2


Antoni Sicras Mainar1, Ruth Navarro Artieda2, Jesús Villoria Morillo3, Ana Esquivias Escobar4
1Dirección de Planificación, Badalona Serveis Assistencials SA, 2Documentación Médica, Hospital Germans Trias i Pujol, Badalona, Barcelona; 3Diseño y Redacción Científica, Medicxact, Alpedrete, 4Departamento Médico, Grünenthal Pharma SA, Madrid, Spain

Background: The purpose of this study was to gather information about analgesic drug therapy in patients with chronic pain and perform cost estimates to guide future cost-effectiveness research in the area.
Methods: Data from patients aged 44 years and over suffering from any chronic condition and receiving regular analgesic drug therapy (for ≥6 months) who attended health care facilities within the area of Badalona during 2008 were collected in a retrospective study. Morbidity profiles were defined according to treatment setting (pain unit, hospital), World Health Organization analgesic step (1–2 versus 3), and a raw cost model based on resource use and work absenteeism was applied. Patients attending the pain unit or the hospital were considered undertreated if they were on step 1–2 analgesics. Multiple regression was used to compare costs between undertreated and non-undertreated patients among those attending the pain unit or the hospital.
Results: Only 410 of 18,157 patients ascertained (2.3%) were on step 3 analgesics. Their direct costs were greater than those of patients on step 1–2 analgesics, although the opposite was true regarding indirect costs. Of patients seen in the pain unit and in the hospital, 2.3% and 20.1%, respectively, were considered undertreated. Regression analyses revealed even greater costs in the subgroup of undertreated patients.
Conclusion: Step 3 analgesics are barely used. Up to one-fifth of patients may be undertreated, generating greater costs than those considered to be properly treated. Regression analyses did not clarify the proportion of their cost excess that was attributable to undertreatment.

Keywords: pharmacoeconomics, analgesic treatment, observational studies, cost-effectiveness

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]